Amyloidosis in Ankylosing Spondylitis

Jayson, M. I. V.; Salmon, P. R.; Harrison, Wendi

doi:10.1093/rheumatology/11.2.78

Cited by 17 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the RA-related secondary amyloidosis frequency has been found to be low. In 2 studies conducted in ankylosing spondylitis patients who lived in Europe, amyloidosis rates were 7% and 9% respectively, as determined by rectal and fat biopsy screenings [37,38]. In the current study, we found 2 (3.2%) cases who had coexistence of ankylosing spondylitis and FMF.…”

Section: Discussionsupporting

confidence: 52%

Evaluation of 61 Secondary Amyloidosis Patients: A Single-Center Experience from Turkey

Hüzmelí¹

2016

Ann Clin Anal Med

View full text Add to dashboard Cite

Amaç: Sekonder amiloidozlu hastaların demografik, klinik ve laboratuar özelliklerini, hastalık sebeplerini, MEFV gen mutasyonlarını ve mortalite oranlarını değerlendirmek. Gereç ve Yöntem: 2007-2013 arasında Cumhuriyet Üniversitesi, Tıp Fakültesi, Nefroloji kliniğine başvuran böbrek yada rektal doku biyopsisiyle sekonder amiloidoz tanısı alan toplam 61 hasta çalışmaya dahil edildi. Demografik özellikler, sekonder amiloidoz sebepleri, MEFV gen mutasyonları, ve son dönem böbrek yetmezliği (SDBY), renal transplantasyon ve mortalite oranları retrospektif olarak değerlendirildi. Bulgular: Etiyolojik açıdan hastaların %62.2'si (38) FMF, %9.8'i (6) bronşiyektazi ve amfizem, %4.9'u (3) tüberküloz, %3.2'si (2) FMF ve ankilozan spondilit birlikteliği, %1.6'sı (1) FMF ve romatoid artrid birlikteliği, %1.6'sı (1) FMF ve sistemik lupus eritematozus birlikteliği, %1.6'sı (1) osteomiyelit, %1.6'sı (1) septik artrit, %1.6'sı (1) crohn hastalığı, %1.6'sı (1) kolon kanseri, %1.6'sı (1) bronşiyektazi ve tüberküloz birlikteliği, %1.6'sı (1) romatoid artrit ve %6.5'i (4) idiyopatik olarak değerlendirildi. Sekonder amiloidozu olan 47 hastanın 32'sinde (%68) nefrotik düzeyde proteinuri saptandı. Sekonder amiloidozlu 45 hastanın MEFV gen mutasyonları incelendi. Hastaların çoğunda M694V mutasyonu vardı. Şaşırtıcı bir şekilde, 3 vakada heterozigot E148Q mutasyonu saptadık. 12 vaka öldü ve bu hastaların 9'u SDBY'idi. SDBY olan 5 vaka böbrek nakli oldu. Tartışma: Bu çalışmada sekonder AA amiloidoz için en yaygın sebep olarak FMF hastalığını bulduk. Daha büyük yada çok merkezli kohortlarda daha ileri çalışmalar yapılmalıdır.

show abstract

Section: Discussionsupporting

confidence: 52%

Evaluation of 61 Secondary Amyloidosis Patients: A Single-Center Experience from Turkey

Hüzmelí¹

2016

Ann Clin Anal Med

View full text Add to dashboard Cite

show abstract

“…2 4 5 Secondary amyloidosis has been considered a rare complication of ankylosing spondylitis,7 8 with hardly any clinical importance.9 As early as 1960, however, amyloidosis was found in 6% of dead patients with ankylosing spondylitis,'0 and in the 1970s the prevalence of secondary amyloidosis in ankylosing spondylitis was estimated to be from 4-4 to 8-6%. [11][12][13] In an earlier study the present author found amyloidosis to be a direct cause of death in 14 of 79 (18%) patients with ankylosing spondylitis.14 The purpose of this study was to establish the mortality and causes of death in patients with ankylosing spondylitis, with a special interest in amyloidosis, using a larger patient sample than in the earlier study,'4 and thus either to confirm or disprove the earlier finding of the high prevalence of secondary amyloidosis in Finnish patients with ankylosing spondylitis.…”

mentioning

confidence: 99%

Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis.

Lehtinen¹

1993

Annals of the Rheumatic Diseases

225

100

View full text Add to dashboard Cite

The mortality and causes of death in 398 patients (47 women, 351 men) with definite ankylosing spondylitis, admitted to hospital for the first time between 1961 and 1969, were investigated. The mean age at first admission was 36 5 years (SD 11.8).After a mean follow up time of 25 7 years, a total of 152 patients (12 women, 140 men) had died. The expected mortality based on the mortality statistics of the general population of the same sex and age was 103-1 (9.4 women and 93 7 men). Thus the overall mortality of the patients with ankylosing spondylitis was 1-5 times that expected. Those patients who had died were significantly older, had a higher erythrocyte sedimentation rate, and more inflamed peripheral joints when first seen than the surviving patients. The main difference between the observed and expected causes of death was the high incidence of deaths from ankylosing spondylitis, which was the underlying cause of death in 27 patients. The mechanism of death in these patients was secondary amyloidosis in 19, cardiovascular complications in six, fracture of the spine in one, and it was not known in one patient. Excess deaths due to circulatory, gastrointestinal and renal diseases, and violence were also observed.

show abstract

“…Ankylosing spondylitis might be associated with amyloidosis of the kidney, rectum or liver vessels, however, since amyloid lesions are reportedly localized to a limited area, the prognosis of this entity is believed to be favorable. [1][2][3][4][5][6][7][8][9][10][11][12] Despite the literature from other countries, there have been no case reports thus far in Japan describing ankylosing spondylitis as a precurser of systemic amyloidosis. In this paper, we report the first Japanese case of amyloidosis following active ankylosing spondylitis, which had systemic lesions and a fatal outcome.…”

Section: Uch Knowledgementioning

confidence: 99%

Systemic Amyloidosis Following Ankylosing Spondylitis Associated with Congestive Heart Failure. A Case Report.

et al. 1995

View full text Add to dashboard Cite

SUMMARYWe report the case of a 38-year-old man who developed fatal, systemic amyloidosis following ankylosing spondylitis. He was admitted for symptoms of congestive heart failure. Based on parotid gland biopsy and echocardiography, he was diagnosed as having systemic amyloidosis following active ankylosing spondylitis. However, the clinical course was rapidly progressive and eventually the patient died of acute necrotizing pancreatitis. The association has been reported thus far in a limited number of cases worldwide. The literature has featured localized lesions and a benign clinical course of the amyloidosis. This case, the first report from Japan, indicates that the amyloidosis associated with ankylosing spondylitis might exhibit a rapidly progressive clinical course, thereby suggesting that in such a case, meticulous treatment is required. (Jpn Heart J 36: 681-688, 1995)

show abstract

Amyloidosis in Ankylosing Spondylitis

Cited by 17 publications

References 0 publications

Evaluation of 61 Secondary Amyloidosis Patients: A Single-Center Experience from Turkey

Evaluation of 61 Secondary Amyloidosis Patients: A Single-Center Experience from Turkey

Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis.

Systemic Amyloidosis Following Ankylosing Spondylitis Associated with Congestive Heart Failure. A Case Report.

Contact Info

Product

Resources

About